LSR-ADC

LSR-ADC is an antibody-drug conjugate (ADC) targeting the lipolysis-stimulated lipoprotein receptor (LSR) for the treatment of epithelial ovarian cancer (EOC). It consists of a specific anti-LSR monoclonal antibody (clone #16-6) conjugated to the cytotoxic payload monomethyl auristatin E (MMAE), a potent microtubule inhibitor. LSR is a component of tricellular tight junctions that is frequently overexpressed in EOC and correlates with poor clinical outcomes. Upon binding to LSR on the surface of cancer cells, the ADC is internalized via endocytosis, leading to the intracellular release of MMAE. MMAE then disrupts microtubule dynamics, inducing G2/M phase cell cycle arrest and triggering apoptosis. Preclinical studies have demonstrated that LSR-ADC possesses significant and selective antitumor activity against LSR-positive ovarian cancer cell lines and xenograft models.

Other names

anti-LSR ADCLSR-targeted ADClipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate